Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Study:

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer`s Disease (AD) With an Optional 26-Week Open Label Extension

Rationale:

n/a

Purpose:

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer`s Disease.

Study Status: Recruiting

Recruiting:
702-483-6030

Condition Intervention Phase
Alzheimer`s Disease Drug: AC-1204
Drug: Placebo
Phase 2/Phase 3

Verified by Accera, Inc. January, 2014

Sponsored by: Accera, Inc.
Information provided by: Accera, Inc.
ClinicalTrials.gov identifier: NCT01741194

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States

Samuel T Henderson, PhD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site